IRVINE, Calif.--(BUSINESS WIRE)--Balt USA LLC, a pioneer in stroke treatment, announced today that it strongly disputes and will vigorously respond to the recent trade secret allegations made by MicroVention, Inc.
On December 22, 2020, MicroVention filed a trade secret complaint in the U.S. District Court for the Central District of California naming Balt USA and four individuals who are current and former Balt employees. MicroVention’s non-specific allegations suggest that these individuals purportedly used MicroVention confidential information to develop products introduced by Blockade Medical, a company acquired by Balt in 2016, and known today as Balt USA.
MicroVention’s complaint comes after Balt USA launched a validity challenge at the U.S. Patent and Trademark Office against a MicroVention patent covering the V-Trak coil system.
Pascal Girin, CEO of Balt, the parent company of Balt USA, stated that “Balt is the oldest company in the neurovascular space and has been developing innovative products for the interventional access and treatment of neurovascular diseases since 1977. These efforts have resulted in the most comprehensive product portfolio in the industry, and Balt has a unique legacy of independently developed neurovascular product offerings. We strongly disagree with the accusations made by MicroVention and will respond accordingly. We are also disappointed that MicroVention chose to target our employees with these unfounded accusations. While others in the industry may be more interested in lawsuits than innovation, we at Balt are fully committed to executing our vision and mission to develop and commercialize lifesaving technologies.”
About Balt:
Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures and distributes the broadest portfolio of products in the neurovascular space and is now focused on expanding its geographic presence in both the USA and China. Visit Balt at https://www.balt-corp.com/.
